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Abstract
The clinical diagnosis of synucleinopathies, including Parkinson’s disease (PD), dementia with Lewy bodies (DLB), and 
multiple system atrophy (MSA), is challenging, especially at an early disease stage, due to the heterogeneous and often non-
specific clinical manifestations. The discovery of reliable specific markers for synucleinopathies would consequently be of 
great aid to the diagnosis and management of these disorders. Real-Time Quaking-Induced Conversion (RT-QuIC) is an 
ultrasensitive technique that has been previously used to detect self-templating amyloidogenic proteins in the cerebrospinal 
fluid (CSF) and other biospecimens in prion disease and synucleinopathies. Using a wild-type recombinant α-synuclein as 
a substrate, we applied RT-QuIC to a large cohort of 439 CSF samples from clinically well-characterized, or post-mortem 
verified patients with parkinsonism or dementia. Of significance, we also studied patients with isolated REM sleep behavior 
disorder (iRBD) (n = 18) and pure autonomic failure (PAF) (n = 28), representing clinical syndromes that are often caused 
by a synucleinopathy, and may precede the appearance of parkinsonism or cognitive decline. The results show that our RT-
QuIC assay can accurately detect α-synuclein seeding activity across the spectrum of Lewy Body (LB)-related disorders 
(LBD), including DLB, PD, iRBD, and PAF, with an overall sensitivity of 95.3%. In contrast, all but two patients with 
MSA showed no α-synuclein seeding activity in the applied experimental setting. The analysis of the fluorescence response 
reflecting the amount of α-synuclein seeds revealed no significant differences between the clinical syndromes associated 
with LB pathology. Finally, the assay demonstrated 98% specificity in a neuropathological cohort of 101 cases lacking LB 
pathology. In conclusion, α-synuclein RT-QuIC provides an accurate marker of synucleinopathies linked to LB pathology 
and may have a pivotal role in the early discrimination and management of affected patients. The finding of no α-synuclein 
seeding activity in MSA seems to support the current view that MSA and LBD are associated with different conformational 
strains of α-synuclein.
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Introduction
Synucleinopathies, including Parkinson’s disease (PD), 
dementia with Lewy bodies (DLB), and multiple system 
atrophy (MSA), are neurodegenerative diseases character-
ized by the intracellular accumulation of toxic α-synuclein 
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(α-Syn) aggregates [62, 67]. In these pathologies, a confor-
mational change (misfolding) of the α-Syn monomer pro-
duces an aggregation nucleus (seed), which can induce the 
conversion of other α-Syn molecules, forming Lewy bod-
ies (LB), the primary histopathological lesion of PD and 
DLB, or other oligodendroglial and neuronal cytoplasmic 
inclusions in MSA [29, 42]. The seeded conversion mecha-
nism, resulting in the self-propagation of misfolded α-Syn, 
is named nowadays as prion-like, due to the analogy to that 
initially identified in prion diseases [27, 53, 65].
Clinically, synucleinopathies show a highly variable 
presentation, response to therapy, and rate of progression. 
Consequently, the prognosis of these conditions is also very 
variable. Lewy body disease (LBD), the most common synu-
cleinopathy, comprising DLB and the large majority of PD 
patients, may manifest clinically with either parkinsonism or 
cognitive decline (or both), with overlapping symptoms with 
both atypical parkinsonisms, including progressive supra-
nuclear palsy (PSP), MSA, and corticobasal degeneration 
(CBD), and neurodegenerative dementias, mainly Alzhei-
mer’s disease (AD) [7, 34, 58]. Moreover, the demonstration 
that clinical conditions such as isolated REM sleep behavior 
disorder (iRBD) and pure/isolated autonomic failure (PAF) 
are often caused by a synucleinopathy [16, 33], further com-
plicates the diagnosis of LBD, but, at the same time, pro-
vides a potential clinical target for the early recognition of 
these patients. In particular, the term iRBD was suggested 
to refer to RBD occurring in the absence of any associated 
neurological sign or other possible cause [30], a condition 
characterized by a high phenoconversion rate to an overt 
synucleinopathy [51]. The identification of a biomarker for 
synucleinopathies would be, therefore, of great value in clin-
ical practice for the differential and early diagnosis, prognos-
tic assessment, and the monitoring of disease progression. 
Furthermore, an accurate early diagnosis would optimize 
the inclusion of patients in clinical trials. Given that imag-
ing with radiotracers, to be applied to research and clinical 
practice, are available for beta-amyloid and tau proteins but 
not for α-Syn, the search for reliable markers for synucle-
inopathies in biological fluids is even more crucial. Unfor-
tunately, misfolded α-Syn, the ideal biomarker candidate, 
is expressed in biological fluids in concentrations below 
the detection level of standard analytical techniques [48]. 
Recently, a novel approach based on the in vitro amplifica-
tion of the pathogenic protein seed obtained by forcing the 
conversion of native monomers into their misfolded coun-
terpart provided the basis to overcome this limitation [4, 
14, 54, 55]. In one of these seeding amyloid assays (SAAs) 
called Real-Time Quaking-Induced Conversion (RT-QuIC), 
the pathogenic seed derived from the CSF, or other bio-
logical fluids or tissues, of an affected patient, is incubated 
with its native counterpart, represented by a recombinant 
protein [69, 4]. Intermittent shaking is then used to favor 
the interaction between the seed and the substrate, forcing 
the conversion of the monomer into its pathogenic counter-
part. The course of the reaction is monitored in real time by 
thioflavin, a fluorescent dye that shows enhanced emission 
upon binding to cross-β structures, a typical feature of amy-
loid fibrils. Given its capacity of identifying misfolded forms 
of prion protein (PrP) from Creutzfeldt–Jakob disease (CJD) 
CSF with a specificity of 100% and a sensitivity of 95–98%, 
RT-QuIC has already been included in the diagnostic criteria 
for the clinical diagnosis of sporadic(s) CJD, the most com-
mon human prion disease [70]. By showing that this assay 
may also accurately discriminate between LBD and other 
parkinsonisms or dementias unrelated to α-Syn, more recent 
studies strongly suggested that CSF RT-QuIC can also be 
applied successfully to synucleinopathies [9, 20, 28, 55, 64], 
especially to those associated with LB pathology. Here, we 
expanded these preliminary results by analyzing the largest 
cohort studied to date, including well-characterized patients 
with parkinsonism and/or dementia. Moreover, we tested 
for the first time a significant number of patients affected by 
iRBD and PAF.
Materials and methods
The study was conducted according to the revised Decla-
ration of Helsinki and Good Clinical Practice guidelines. 
Informed consent was given by study participants or the next 
of kin.
Patients and controls
We analyzed 439 CSF samples submitted to the Neuropa-
thology Laboratory (NP-Lab) at the Institute of Neurological 
Sciences of Bologna (ISNB) between 2005 and 2019. The 
cohort included 122 patients with a post-mortem CNS neu-
ropathological assessment (i.e., “neuropath” cases), and 317 
patients in which the clinical diagnosis was reached after a 
comprehensive evaluation and a significant follow-up (i.e., 
“clinical” cases). The first group encompassed cases of pro-
gressive dementia, more often with a rapidly progressive 
course, or of atypical parkinsonism, and included the fol-
lowing diagnostic categories: DLB, AD, CJD, Frontotem-
poral lobar degeneration, MSA, PSP, Encephalitis, Vascular 
dementia, and other dementias. The “neuropath” group was 
further divided into LB α-Syn+ and LB α-Syn− subgroups 
based on protein aggregate assessment by immunohisto-
chemistry (see below for further details).
The “clinical” group included 62 cases lacking symptoms 
and signs suggesting an underlying progressive neurodegen-
erative disorder (e.g., chronic headache, narcolepsy type 1 
with or without associated RBD; for the complete list see 
Supplementary Table 1, online resource) and 255 patients 
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fulfilling the current diagnostic criteria of probable or clini-
cally established disease for one of the following disorders/
syndromes: iRBD [57], PAF [13, 23], PD [50], MSA [26], 
PSP [31], CBS [3], DLB [41], and AD/prodromal AD (hence 
abbreviated as AD) [19]. Moreover, the group included ten 
patients with the clinical diagnosis of PD (n = 8) or DLB 
(n = 2) carried single allele mutations known to be asso-
ciated with LBD in the glucocerebrosidase gene (GBA) 
(N370S, L444P, R131C, E326K, n = 9) or in the Leucine 
Rich Repeat Kinase 2 gene (LRRK2) (G2019S, n = 1).
Clinical assessment and diagnostic criteria
For each patient, we collected the clinical history, and 
the results of neurological examination(s) and diagnostic 
investigations, including, when available, brain magnetic 
resonance imaging (MRI, n = 275), cerebral 129I-ioflupane 
SPECT (DaTSCAN) (n = 147), cardiac 123I-metaiodo-
benzylguanidin (MIBG)-SPECT (n = 88), and all-night 
polysomnography (PSG, n = 163) (see also Supplementary 
Table 2, online resource). For AD and DLB groups, results 
of neuropsychological examination(s), data of Mini-Mental 
State Examination (MMSE), and CSF values of AD core 
biomarkers were also obtained. All patients with suspected 
autonomic failure (AF) (n = 170) were assessed by a bat-
tery of cardiovascular reflex tests, including head-up tilt 
test (10 min at 65°), Valsalva maneuver (40 mm Hg for 
15 s), deep breathing (6 breaths/min), and sustained hand-
grip (one-third of maximal effort for 5 min). All patients 
with the diagnosis of narcolepsy type 1 (n = 15) underwent 
the multiple sleep latency test, polygraphic assessment of 
cataplexy, and the evaluation of CSF orexin levels. After 
CSF collection, most patients belonging to the “clinical” 
group were longitudinally followed-up at the ISNB [i.e., the 
follow-up duration was > 2 years in 116 cases (36.6%), and 
> 1 year in 161 cases (50.8%)]. Only patients with a prob-
able or clinically established (for PD only) diagnosis at last 
follow-up of iRBD, PAF, PD, MSA, PSP, CBS, DLB, and 
AD, according to international criteria, were included into 
the study cohort. The cases fulfilling the criteria for more 
than one probable disease (e.g., concurrent probable diag-
nosis of PSP and MSA) were excluded. The term iRBD was 
used to refer to RBD occurring in the absence of any associ-
ated neurological sign or other possible cause [30]. Finally, 
to increase the accuracy of clinical diagnosis, only patients 
with PAF presenting with AF as the sole clinical manifesta-
tion for at least 5 years were considered [25].
Given that the patients with iRBD and PAF may develop 
cognitive and/or motor symptoms/signs and convert to other 
clinical syndromes, including DLB, PD, and MSA, we eval-
uated separately the phenoconversion process in subjects 
diagnosed with these prodromic disorders at time of CSF 
collection but receiving another clinical diagnosis at last 
follow-up.
Neuropathological studies
Neuropathological examination was performed using stand-
ardized procedures as described [37]. Briefly, according to 
the autopsy protocol of NP-Lab at ISNB, the brain is divided 
sagittally and the right hemibrain is fixed in 10% buffered 
formalin, while the left one is sectioned coronally and then 
immediately frozen at − 80 °C in sealed plastic bags. The 
formalin-fixed left hemibrain is serially sectioned in 1 cm 
slices, and tissue blocks from 24 regions are processed rou-
tinely to obtain paraffin-embedded brain tissue blocks [47].
Seven μm-thick sections from each block were stained 
with hematoxylin–eosin for screening. Also, immunohis-
tochemistry with antibodies specific for α-Syn (LB509, 
dilution 1:100, Thermo Fisher Scientific, and KM51, dilu-
tion 1:500, Novocastra), phospho-tau (p-tau) (AT8, dilu-
tion 1:100, Innogenetics), Aβ (4G8, dilution 1:5000, Sig-
net Labs), and PrP (3F4, dilution 1:400, Signet Labs) was 
applied to all cases using several brain regions, mainly 
following established consensus criteria [1, 2, 43, 46]. An 
experienced neuropathologist (P.P.) formulated the final 
diagnosis, assigned the Braak stage of LB-related pathol-
ogy [2], and classified each case according to the level of 
AD neuropathologic change (ABC score) [1, 43].
CSF collection and analyses
CSF samples were obtained by lumbar puncture (LP) at the 
L3/L4 or L4/L5 level following a standard procedure. Most 
CSF samples of the clinical group (299 out of 317) were col-
lected (i.e., LP performed) at the same site (IRCCS-ISNB) 
and homogeneously handled by trained personnel. In con-
trast most specimens (116 out of 122) from the patients with 
post-mortem confirmation derived from general neurologic 
practice at various sites, since they were recruited through 
the Italian National Surveillance program for prion disease. 
All samples, irrespective of their origin, were divided into 
aliquots of 400–500 μl, and stored in polypropylene tubes at 
− 80 °C until analysis.
CSF total-tau (t-tau) levels were measured in all cases. 
For clinical classification purposes, CSF p-tau and Aβ1–42 
(Aβ42) analyses were limited to AD and DLB cases. Aβ1–40 
(Aβ40) was evaluated in the AD and control cohorts to 
calculate the ratio between Aβ42 and Aβ40 according to a 
previously published formula [(Aβ42)/(Aβ40) × 10] [5]. We 
measured AD core biomarkers prospectively in a routine 
clinical setting. CSF t-tau, p-tau, Aβ42, Aβ40, and levels 
were analyzed using commercially available ELISA kits 
(INNOTEST htau-Ag, INNOTEST p-tau181, INNOTEST 
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Aβ42, and INNOTEST Aβ40). The results of these analyses 
are reported in Supplementary Table 3, online resource.
Purification of human recombinant α‑synuclein
Glycerol stock of E. coli bacteria containing the vector for 
wild-type (wt) human α-Syn expression was obtained from 
Dr. Byron Caughey’s lab. The purification of the recom-
binant α-Syn was performed as reported [28], with minor 
modifications. Bacteria from the glycerol stock were inocu-
lated into 5 ml of Luria Broth (LB, Sigma) containing 50 µg/
ml of kanamycin (Sigma) and let grow for 4–5 h at 37 °C 
with continuous agitation at 250 rpm. The initial culture was 
then added to 1 l of LB containing 50 µg/ml of kanamycin 
plus the overnight express auto-induction system (Merk-Mil-
lipore) in a full baffled flask. Cells were grown in a shaking 
incubator at 37 °C, 200 rpm overnight. The next day, the cul-
ture was split into four 250 ml flasks, and bacteria were har-
vested by centrifugation at 3200 × g for 10 min at 4 °C. The 
pellet was gently re-suspended in 25 ml osmotic shock buffer 
containing 40% sucrose, 2 mM EDTA, and 30 mM Tris 
at pH 7.2 using a 25 ml serological pipette and incubated 
10 min at room temperature under mild agitation. Next, the 
suspension was centrifuged at 7900×g, 20 m at 20 °C. The 
supernatant was discarded, and the pellet was re-suspended 
in 10 ml of ice-cold water for each pellet. Suspensions were 
pooled into two 50 ml tubes to a final volume of 20 ml per 
tube. 20 µl of saturated  MgCl2 was added to each 20 ml sus-
pension and incubated on ice for 3 min under mild rocking. 
Next, the suspension was centrifuged at 9000×g, 30 min at 
4 °C. The pellet was discarded, and the supernatant collected 
into a 100 ml glass beaker containing a magnetic stir bar. 
The pH was reduced to pH 3.5 by adding 400–600 µl HCl 
1 M and incubated under stirring for 10 min at room tem-
perature. Tubes were centrifuged at 9000 ×g for 30 min at 
4 °C, the pellet was discarded, and the supernatant collected 
into a fresh 100 ml glass beaker containing a magnetic stir 
bar. The pH was adjusted to 7.5 by adding 400–600 µl NaOH 
1 M. The protein extract was filtered through a 0.22 µm filter 
(Merk-Millipore), loaded into a Ni–NTA column (Qiagen) 
on an NGC chromatographic system (Bio-Rad) and washed 
with 20 mM Tris, pH 7.5 at room temperature. The column 
was further washed with 50 mM imidazole in Tris 20 mM, 
pH 7.5, generating a peak that was not collected. A linear 
gradient up to 500 mM imidazole in 20 mM Tris, pH 7.5 was 
performed, and the peak was collected between 30 and 75% 
of imidazole buffer (150 and 375 mM, respectively). This 
peak was loaded onto an anion exchange column Q-HP (GE 
Healthcare) and washed in Tris 20 mM, pH 7.5, followed by 
another washing in 100 mM NaCl in Tris 20 mM, pH 7.5. A 
linear gradient up to 500 mM of NaCl in Tris 20 mM pH 7.5 
was performed to collect the peak between 300 and 350 mM 
NaCl. The recovered fractions were pooled together and 
filtered through a 0.22 µm filter and dialyzed against water 
overnight at 4 °C using a 3.5 kDa MWCO dialysis mem-
brane (Thermo-Scientific). The next day, the protein was 
moved into fresh water and dialyzed for four more hours. 
The protein concentration was measured with a spectropho-
tometer using a theoretical extinction coefficient at 280 nm 
of 0.36 (mg/ml)-1/cm. Finally, the protein was lyophilized 
using a lyophilizer (Thermo-Scientific) for 6 h and stored 
in aliquots at a final concentration of 1 mg/ml once re-sus-
pended into 550 µl of phosphate buffer (PB) 40 mM, pH 
8.0. Lyophilized aliquots were stored at − 80 °C until usage.
The real‑time quaking‑induced conversion assay 
(RT‑QuIC)
The RT-QuIC reactions were performed following an estab-
lished protocol [28]. Black 96-well plates with a clear bot-
tom (Nalgene Nunc International) were pre-loaded with 
six 0.8 mm silica beads (OPS Diagnostics) per well. CSF 
samples were thawed and vortexed 10 s before use. Fifteen 
µL of CSF were added as seed to trigger the reaction in 85 
µL of buffer containing 40 mM PB, pH 8.0, 170 mM NaCl, 
10 mM thioflavin-T (ThT), 0.0015% sodium dodecyl sulfate 
(SDS), and 0.1 g/l of recombinant α-Syn filtered using a 
100 kDa MWCO filter (Pall-Life Sciences). The plate was 
sealed with a plate sealer film (Nalgene Nunc International) 
and incubated into Fluostar Omega (BMG Labtech) plate 
reader at 42 °C with intermittent double orbital shaking 
at 400 rpm for one minute, followed by 1-min rest. ThT 
fluorescence measurements were taken every 45 min using 
450 nm excitation and 480 nm emission filter. To overcome 
batch-to-batch variations of α-Syn activity and the intrinsic 
experimental variability, relative fluorescent units (RFU) 
for every time point were normalized for the maximum of 
the intensity of each experimental plate and expressed as a 
percentage. Samples were run in quadruplicates and deemed 
positive when at least two out of four replicates reached the 
threshold, calculated as the average normalized fluorescence 
value of the first 10 h of the run of the 101 neuropathological 
control samples, plus 30 standard deviations. The analysis 
was repeated when only one replicate crossed this threshold.
Statistical analysis
RT-QuIC relative fluorescence responses were analyzed and 
plotted using the software Graphpad Prism 8.3. The area 
under the curve (AUC), the maximum intensity of fluores-
cence (Imax), and the lag phase were extracted, and the nor-
mality of the distribution of these variables from each group 
was assessed using the Kolmogorov–Smirnov test. The com-
parison among groups was performed using the one-way 
ANOVA followed by Tukey’s multiple comparisons post hoc 
test. P values < 0.05 were considered statistically significant. 
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Unless otherwise stated, the error bars indicate the standard 
deviation (SD).
Results
Patients
Demographic data, symptom scores, and numbers and 
results of performed diagnostic investigations for all patient 
groups are summarized in Table  1 and Supplementary 
Tables 2 and 3, online resource.
CSF Syn RT‑QuIC identifies Lewy body‑related 
pathology with high sensitivity and specificity
Our preliminary analyses using the wild-type α-Syn and 
the protocol published by Groveman et al. [28] showed 
high sensitivity of the RT-QuIC assay in patients with 
LBD. Thus, to thoroughly and reliably assess the accu-
racy of the test, we initially examined CSF samples from 
21 subjects demonstrating various extents of LB-related 
pathology at post-mortem examination (i.e., Braak stage 
1–6, Fig. 1, and Table 2), 101 subjects lacking LB-related 
pathology assessed by immunostaining, and 62 subjects 
who did not manifest symptoms or signs suggestive of a 
progressive neurological disorder. In the neuropathologi-
cally verified cohort (Fig. 2a), the CSF α-Syn RT-QuIC 
yielded an overall specificity of 98.0% and a sensitivity 
of 95.2% (100% in definite DLB), whereas the specific-
ity calculated on the clinical controls was 98.4% (61/62 
negatives), or 97.6% (40/41 negatives) when only the sub-
group of controls age-matched (64.0 ± 6.2 years) with the 
iRBD, PAF, and PD groups was considered. Unexpected 
positive results were limited to two cases with a primary 
neuropathological diagnosis of Wernicke’s encephalopa-
thy and Alzheimer’s disease, which showed no detect-
able α-Syn deposits, despite the positivity by RT-QuIC, 
Table 1  Demographic findings of the study cohort
LP lumbar puncture, DLB dementia with Lewy bodies, AD Alzheimer’s disease, PD Parkinson’s disease, PSP progressive supranuclear palsy, 
CBS corticobasal syndrome, MSA multiple system atrophy, PAF pure autonomic failure, iRBD isolated REM sleep behaviour disorder, α-Syn 
α-synuclein
a The follow-up duration was calculated from LP to the last visit (or death)
b Neuropathological cases diagnosed as Creutzfeldt–Jakob disease (n = 51), malignancy (n = 3), vascular disease (n = 6), encephalitis (n = 10), 
Wernicke’s encephalopathy (n = 3), frontotemporal lobar degeneration plus amyotrophic lateral sclerosis (n = 1), non-specified tauopathy (n = 1), 
and dementia lacking distinctive pathology (n = 6)
c 53 clinically established and 18 probable cases
d For a detailed list, see Supplementary Table 1 (online resource)
Diagnostic category n Female (%) Age at LP (years) Time between clinical 
onset and LP (mos)
Follow-up 
duration 
(mos)a
Time between clinical 
onset and last visit 
(years)
Definite NP cohort
 LB-α-Syn+ 21 9 (42.9) 75.8 ± 6.3 12.2 ± 28.9 3.9 ± 8.8 2.2 ± 2.5
  DLB 14 6 (42.9) 76.9 ± 5.4 17.3 ± 34.1 5.0 ± 10.4 1.7 ± 2.9
  Dementia with incidental LB 7 3 (42.9) 74.3 ± 7.7 2.0 ± 1.8 1.1 ± 1.1 0.3 ± 0.2
 LB-α-Syn− 101 45 (44.5) 68.5 ± 9.9 3.7 ± 13.4 4.5 ± 12.2 0.7 ± 1.8
  AD 17 9 (52.9) 76.4 ± 7.5 1.6 ± 2.5 1.9 ± 2.6 0.3 ± 0.3
  PSP 1 0 (0) 64 108 30 11.5
  MSA 2 1 (50.0) 62.5 ± 7.8 40.5 ± 54.4 68.5 ± 28.9 9.1 ± 2.1
  Syn−  controlsb 81 35 (43.2) 66.9 ± 9.9 1.9 ± 2.1 3.2 ± 7.6 0.4 ± 0.7
Clinical cohort
 DLB 34 9 (26.5) 73.2 ± 7.5 78.8 ± 105.8 14.9 ± 21.4 7.8 ± 8.7
 AD 43 22 (52.2) 66.3 ± 7.8 43.4 ± 39.7 12.7 ± 15.8 4.7 ± 3.5
 PSP/CBS 30 19 (63.3) 70.7 ± 6.7 47.0 ± 32.9 8.9 ± 15.0 4.7 ± 2.8
 MSA 31 12 (38.7) 60.7 ± 8.6 55.2 ± 42.0 23.4 ± 16.3 6.4 ± 3.6
 PDc 71 19 (26.8) 62.2 ± 8.8 56.8 ± 45.8 31.6 ± 35.9 7.4 ± 4.2
 PAF 28 11 (39.3) 65.5 ± 8.5 119.3 ± 62.5 43.9 ± 50.4 13.6 ± 6.9
 iRBD 18 6 (33.3) 68.2 ± 7.7 71.5 ± 60.7 10.6 ± 15.1 6.9 ± 4.7
 Clinical  controlsd 62 30 (48.4) 53.9 ± 15.4 158.7 ± 152.5 30.2 ± 27.5 15.5 ± 13.5
Total 439 182 (41.5) 65.3 ± 11.4 59.6 ± 85.6 18.3 ± 27.6 6.5 ± 7.5
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and one 76 years old clinical control with a diagnosis of 
peripheral sensory neuropathy.  
Having established the very high specificity and sensi-
tivity of the assay as a marker of LB-related pathology in a 
neuropathologically confirmed cohort and in non-neurode-
generative clinical controls, we then examined the perfor-
mance of the assay in a well-characterized patient population 
representing the whole clinical spectrum of LBD, namely 
parkinsonism, dementia, iRBD, and PAF.
Performance of α‑Syn RT‑QuIC in patients 
with parkinsonism
To evaluate the performance of the RT-QuIC in patients with 
parkinsonism, we compared well-characterized patients, ful-
filling clinical criteria for a probable or clinically established 
disease of, respectively, PD, MSA, and PSP/CBS. Positive 
seeding activity was consistently detected only in PD, but 
neither in PSP/CBS nor, unexpectedly, in MSA (Fig. 2b). In 
the probable PD cohort, the assay yielded a sensitivity of 
94.4%, whereas the specificity was 100% against patients 
with PSP/CBS and 93.5% against those with MSA (Table 3). 
Among the 67 PD patients who tested positive by RT-QuIC, 
48 (71.6%) showed a full 4/4 positive response, 13 (19.4%) 
gave 3/4, and 6 (8.9%) gave 2/4 (Supplementary Table 4, 
online resource). All the patients carrying a mutation in GBA 
tested positive by RT-QuIC, whereas the one carrying the 
mutation in LRRK2 did not show any α-Syn aggregation. 
The latter result is in line with those of a previous study 
demonstrating a much lower sensitivity of the RT-QuIC in 
LRRK2-PD than in idiopathic PD [24]. Discordant results 
were limited to two patients with probable MSA who showed 
α-Syn seeding activity and three with probable idiopathic 
PD who tested negative. A detailed analysis of the clinical 
features of patients yielding unexpected results revealed that 
in the three idiopathic PD subjects, the disease severity was 
mild (baseline score at the UPDRS scale section III: 16, 14, 
and 8), and two of them presented with isolated, unilateral 
tremor. One patient with the diagnosis of probable MSA had 
an “atypical” long clinical history of more than 10 years, 
characterized by a slowly progressive cerebellar syndrome 
and late appearance of parkinsonism and AF. In contrast, 
the other one had typical MSA features, including the early 
association of autonomic, pyramidal, extrapyramidal and 
cerebellar signs, and a more rapid progression of symptoms.
Overall, these results indicate that our RT-QuIC set-up 
can accurately detect α-Syn seeding activity in the CSF of 
subjects with probable/clinically established PD and can 
discriminate with high precision typical PD from atypical 
parkinsonism such as PSP/CBS, and MSA.
Performance of α‑Syn RT‑QuIC in patients 
with prodromal syndromes: iRBD and PAF
Given the lack of clinical criteria that reliably establish 
the “probable” LB-related etiology of these syndromes at 
Fig. 1  Distinctive α-Syn pathology in patients with LBD and MSA. 
a Moderate number of LBs and Lewy neurites in the medulla of a 
case with incidental LB pathology (case #18); b numerous pathologi-
cal aggregates of α-Syn in the locus coeruleus (case #8); c single and 
multiple LB inclusions in the neurons of substantia nigra (case #8); 
d numerous LBs and positive dendrites in the amygdala (case #3); e 
moderate number of LBs and positive dendrites in the temporal neo-
cortex (case #1); f numerous glial cytoplasmic inclusions (GCIs) in 
oligodendroglia in the internal capsule of a patient with MSA-P; the 
two boxes on the left show high magnifications of two GCIs (basal 
ganglia, upper box) and one neuronal cytoplasmic inclusion (pons, 
lower box)
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disease onset, we focused the analysis on clinically well-
characterized patients (see “Materials and methods”) who 
received an adequate clinical follow-up.
In the iRBD cohort, the assay showed α-Syn seeding 
activity in 18/18 patients (Fig. 2c, blue curve), thus yield-
ing a sensitivity of 100%. Among these patients, 11 (61.1%) 
showed a full 4/4 positive response, 5 (27.8%) gave 3/4, 
and 2 (11.1%) gave 2/4 (Supplementary Table 4, online 
resource). Interestingly, one patient with the diagnosis of 
probable MSA at follow-up who had only RBD and AF at 
the time of LP tested negative by RT-QuIC. Furthermore, the 
assay did not show any seeding activity in 11/11 narcoleptic 
patients affected by RBD features, resulting in a specificity 
of 100% towards this clinical mimic.
Similarly, in the PAF cohort (Fig. 2c, red curve), 26 out 
of 28 samples showed α-Syn seeding activity, resulting in 
a sensitivity of 92.9%. Among the 26 positive patients, 22 
(84.6%) showed a full 4/4 positive response, 3 (11.5%) 
gave 3/4, and only 1 (3.8%) gave 2/4 (Supplementary 
Table 4, online resource). Of notice, of the two PAF sub-
jects tested negative by RT-QuIC, one had clinical history 
relevant for intermittent diplopia and positivity of anti-
ganglioside GQ1b antibody in serum indirectly suggesting 
a possible underlying autoimmune etiology. At the same 
time, the other one did not show any neurologic symptoms, 
but demonstrated a normal adrenergic cardiac innerva-
tion at MIBG-SPECT, a finding that has been consistently 
associated with MSA, but not with PD and DLB [11, 63].
Interestingly, two patients of the probable MSA group, 
who had a diagnosis of PAF or PAF plus RBD at the time 
of LP, did not show any α-Syn seeding activity. More 
details about the patients who underwent phenoconver-
sion from prodromic syndromes to MSA, PD, and DLB are 
shown in Supplementary Table 5, online resource.
Overall, these results indicate that RT-QuIC can reli-
ably detect pathogenic species of α-Syn in the CSF of 
patients affected by PAF and iRBD, and can discriminate 
them from RBD associated with narcolepsy or MSA.
Table 2  Demographic and neuropathological features of definite cases with LB-Syn+
LP lumbar puncture, NP neuropathologic, DLB dementia with Lewy bodies, AD Alzheimer’s disease, CAA cerebral amyloid angiopathy, CNS 
central nervous system, sCJD sporadic Creutzfeldt–Jakob disease, PART primary age-related tauopathy
a Dementia with incidental LB co-pathology
b sCJD subtypes were defined in accordance with Parchi et al. [47]
c PART was diagnosed according to Crary et al. [18]
List of cases Sex Age at LP Age at death Primary NP diagnosis Secondary NP diagnosis McKeith stage Braak stage
Case #1 F 79 79 DLB AD (low) Neocortical 6
Case #2 F 81 81 DLB AD (low) Neocortical 6
Case #3 F 79 81 DLB AD (intermediate) Neocortical 6
Case #4 M 77 77 DLB AD (intermediate) Neocortical 6
Case #5 M 63 65 DLB AD (high) Neocortical 6
Case #6 M 77 77 DLB AD (intermediate) Neocortical 6
Case #7 F 81 81 DLB AD (intermediate) Neocortical 6
Case #8 M 80 80 DLB AD (intermediate) Neocortical 6
Case #9 F 82 83 DLB AD (intermediate) Neocortical 5
Case #10 M 71 72 DLB AD (low) Neocortical 5
Case #11 M 73 73 DLB AD (low) Neocortical 5
Case #12 F 76 77 DLB AD (intermediate), CAA, subcorti-
cal arteriosclerotic encephalopa-
thy
Limbic 4
Case #13 M 73 73 DLB AD (intermediate), CAA Limbic 4
Case #14 M 83 83 DLB AD (intermediate), CAA Limbic 4
Case #15a M 67 67 sCJD  MM1b DLB Neocortical 5
Case #16a F 73 73 sCJD  VV2b DLB, AD (intermediate), CAA Neocortical 5
Case #17a F 75 76 Primary CNS lymphoma PART c Limbic 4
Case #18a M 87 87 Metabolic encephalopathy AD (low), lacunar stroke Brainstem 3
Case #19a M 72 73 sCJD  VV2b AD (low) Brainstem 2
Case #20a M 81 81 sCJD MV2K + 2Cb AD (low) Brainstem 1
Case #21a F 65 65 sCJD  MM1b None Brainstem 1
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Performance of wt‑Syn RT‑QuIC in patients 
with dementia
Finally, we assessed the ability of the RT-QuIC to detect 
α-Syn seeding activity in cases with dementia. To this aim, 
we grouped the certain cases who received post-mortem 
examination, with the clinical cohorts of probable AD and 
probable DLB. In this population (Fig. 1d, Table 3), the 
assay yielded a sensitivity of 97.9% for DLB (100% in the 
definite group, and 97.1% in the clinical group), whereas 8 
out of 60 AD cases tested gave a positive signal, resulting in 
86.7% specificity towards AD (83.7% when only the clinical 
AD cases were considered). Among patients with definite or 
probable DLB, who tested positive by RT-QuIC, 39 (83.0%) 
showed a full 4/4 positive response, 6 (12.7%) gave 3/4, 
and only 2 (4.2%) gave 2/4 (Supplementary Table 4, online 
resource).
All combined, these results indicate that the α-Syn RT-
QuIC is a highly sensitive and specific assay for the detec-
tion of α-Syn seeding activity in the CSF of subjects with 
either probable or confirmed LB-related pathology. As sum-
marized in Table 3, the overall sensitivity of the assay in 
identifying definite (n = 20) or probable (n = 144) LB-related 
synucleinopathies (DLB + PD + iRBD + PAF) was 95.3% 
(164/172).
Comparison of relative RT‑QuIC seeding activity 
across the LBD clinical spectrum
We also analyzed the main parameters describing the kinetic 
curve of the RT-QuIC. As expected, there was a significant 
difference in both the Imax (Fig. 3a) and the AUC (Fig. 3c) 
between each of the LB-related groups (PD, DLB, iRBD, 
and PAF) and the “negative” groups (MSA, PSP/CBS, AD, 
and clinical controls). However, within LB positive groups, 
we found no statistically significant differences in any of 
the parameters mentioned above, although the DLB group 
showed a slight trend towards a higher Imax and AUC. Over-
all, the mean maximum fluorescence intensity of the “posi-
tive” groups was approximately 80% (relative to the Imax 
reached in every single experiment), whereas the lag phase 
(Fig. 3b) varied between 10 and 24 h, regardless the patho-
logical group.
These results suggest that, although the α-Syn RT-QuIC 
can readily set apart LB-related pathologies from LB 
Fig. 2  Kinetic curves of α-Syn seeding activity measured by RT-
QuIC. a Seeding activity of neuropathologically confirmed LB 
α-Syn + cases (n = 21). Each curve depicts the average of quadrupli-
cates. Standard deviation (SD) was hidden to make the image more 
readable; b comparison among PD (purple line, n = 71), MSA (yellow 
line, n = 33), and PSP/CBS (pale blue line, n = 31) clinical cases; c 
comparison among iRBD (blue line, n = 18), PAF (red line, n = 28), 
and narcolepsy type 1 plus RBD (gray line, n = 11) clinical cases; 
d comparison between DLB (green line, n = 48) and AD (dark gray 
line, n = 60). Clinical and neuropathologically confirmed cases are 
grouped together. Each curve represents the average of the group, 
error bars indicate the SD, and the black dashed line indicates the 
threshold. RFU values are normalized to percentage against the maxi-
mum intensity of fluorescence of the respective experimental plate
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independent pathologies, it has no discriminatory power 
among synucleinopathies, with the relevant exception of 
the MSA cases, which behaved as the negative control 
group in this experimental setting.
Analysis of the assay reproducibility
We ran positive and negative controls on each plate. After 
normalization, there were no significant differences between 
intra-batch and batch-to-batch runs in the main parameters 
Table 3  Sensitivity and 
specificity of the α-Syn 
RT-QuIC assay across the 
diagnostic groups
Pos positive, Neg negative, AD Alzheimer’s disease, PSP progressive supranuclear palsy, CBS corticobasal 
syndrome, MSA multiple system atrophy, DLB Dementia with Lewy bodies, PD Parkinson’s disease, iRBD 
isolated REM sleep behaviour disorder, PAF pure autonomic failure, α-Syn α-synuclein
Bold symbol highlights the sensitivity of the assay in the two most significant diagnostic group and its 
specificity against the LB-associated α-Syn negative controls
a Both neuropathologically confirmed and clinical cases
Diagnostic category n Pos Neg Sensitivity (%) Specificity (%)
Definite NP cohort
 LB-α-Syn+ 21 20 1 95.2
  Definite DLB 14 14 0 100
  Dementia with incidental LB 7 6 1 85.7
 LB-α-Syn− 101 2 99 98.0
  AD 17 1 16 94.1
  PSP 1 0 1 100
  MSA 2 0 2 100
  Syn− controls 81 1 80 98.8
Clinical cohort
 AD 43 7 36 83.7
 Clinical controls 62 1 61 98.4
 PSP/CBS 30 0 30 100
 MSA 31 2 29 93.5
 DLB 34 33 1 97.1
 PD 71 67 4 94.4
 iRBD 18 18 0 100
 PAF 28 26 2 92.9
 All LB-related  synucleinopathiesa 172 164 8 95.3
Fig. 3  Parameters describing the kinetics of α-Syn aggregation in 
the RT-QuIC assay. a Comparison among the Imax of each group; b 
comparison of the lag phase of the positive groups; c comparison of 
the AUC of each diagnostic group analyzed. Box plot colors match 
those represented in the kinetic curves. Box plots show the range and 
the average of the distribution. Symbols indicate the outlier accord-
ing to Tukey test. Statistical analyses were conducted using one-way 
ANOVA, resulting in a significance of p < 0.0001 (****) between 
each of the positive groups against the negatives
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describing the kinetic curve of the RT-QuIC (i.e., Imax, 
lag phase, and AUC), using the same positive or negative 
control sample (Supplementary Fig., online resource). The 
intra-batch coefficient of variation (CV) of the Imax, the 
most significant parameter to determine whether a sample 
is “positive” or “negative” varied between 7.4 and 22.2% 
(median = 13.7%) in the positive control and between 7.8 
and 39.6% (median = 11.9%) in the negative control, while 
the inter-batch CVs for the same parameter was, respectively, 
17.6% in the positive control, and 36.4% in the negative one. 
All CVs for the other two parameters (lag phase and AUC) 
are provided in supplementary Table 8 (online resource).
In a total of 439 sample runs, an unclear result (one 
positive well) occurred 28 times (6.4%), and in most cases 
(85.7%) involved samples yielding a negative result at the 
second test (Supplementary Table  6, online resource). 
Finally, all but three of the 22 positive samples that we tested 
three times using different substrate batches, confirmed the 
positive result of the first run in both repetitions (Supple-
mentary Table 7, online resource). As the only exceptions, 
two samples with a two out of four positivity gave unclear 
results in the second run, but confirmed the positivity in the 
third one, while a third sample gave a one out of two as the 
third result after two positive results. However, in none of 
them, there was a change in the diagnostic decision (positive 
vs. negative).
Discussion
Emerging ultrasensitive techniques investigating the seeding 
aggregation of various amyloidogenic proteins currently pro-
vide the highest expectations towards the goal of improving 
accuracy and early diagnosis of neurodegenerative diseases, 
especially of those lacking reliable diagnostic biomarkers 
such as DLB, PD, and the Frontotemporal lobar degen-
eration spectrum. Following the success obtained in prion 
disease [4, 17, 22, 40, 45, 69], these assays have recently 
shown promising pilot results also for synucleinopathies [20, 
28]. In these studies, α-Syn RT-QuIC has been applied to 
CSF samples from PD, DLB, and MSA patients using dif-
ferent experimental set-ups [20, 28]. Furthermore, protein 
misfolding cyclic amplification, another SAA, has also been 
exploited to demonstrate α-Syn aggregates in the CSF of 
PD patients [15, 60]. While the first two studies with RT-
QuIC demonstrated a full specificity of the assay, subsequent 
studies reported a significant decrease in specificity rang-
ing from 82 to 92% [24, 64]. Thus, the impact on diagnos-
tic criteria and their clinical applicability is still hampered 
by the limited number of patients analyzed, especially in 
the early disease stages, and the less than optimal overall 
diagnostic accuracy obtained in some replication studies [9, 
24, 64]. In the present study, we obtained an almost full 
specificity in the largest cohort studied to date, including 
many cases verified neuropathologically post-mortem and, 
for the first time, a significant number of patients affected by 
prodromal syndromes such as iRBD and PAF. Overall, our 
results demonstrate that, in the applied experimental condi-
tions, the positivity of CSF α-Syn RT-QuIC represents a 
very robust biomarker for LB-related disorders across their 
entire clinical spectrum. We believe that the accuracy of 
our results depends on the experimental set-up, and, most 
critically, on the chosen recombinant substrate. Indeed, 
at variance with all the RT-QuIC studies with suboptimal 
specificity cited above, our assay demonstrated a reduced 
lag phase, which, according to the previous studies in CJD, 
significantly increases the performance of the assay [22, 45]. 
Moreover, this is the second study using the experimental 
conditions put forward by Groveman et al. [28], which also 
demonstrated a very high specificity. To obtain an accurate 
estimate of the diagnostic value of our assay, we selected, in 
addition to neuropathologically verified cases, well-charac-
terized clinical PD and DLB cohorts with a significant clini-
cal follow-up. However, given the much higher complexity 
of the real clinical world, it is foreseeable that RT-QuIC will 
also detect α-Syn seeding activity in a significant percent-
age of patients not fulfilling current criteria for probable PD 
or DLB, resulting in a significant impact on current diag-
nostic criteria for both disorders. Similarly, RT-QuIC will 
likely play a significant role in the identification of patients 
with prodromal PD and DLB, which is of high interest for 
clinical studies with disease-modifying drugs. Indeed, it is 
well established that by the time patients receive a diagno-
sis, they are typically far along in their disease progression, 
and that the early diagnosis will be essential for maximiz-
ing the chances of effective disease-modifying treatment. It 
is also increasingly clear that PAF and iRBD are the most 
useful clinical syndromes for identifying prodromal synu-
cleinopathies. In one 4-year prospective cohort, individuals 
who presented initially with PAF had a 34% risk for con-
verting to LBD or MSA, especially if they also had RBD 
[35]. Similarly, patients with iRBD who are followed-up 
long enough, almost invariably go on to develop PD or other 
synucleinopathies [32, 51]. We have shown that the CSF of 
patients with PAF and iRBD harbors α-Syn seeding activity 
that is comparable to those with PD or DLB. This significant 
result confirms that most patients with iRBD and PAF have 
an LBD, but, most importantly, demonstrates that patients 
with LB-related synucleinopathies can be identified early in 
the course of the disease with high accuracy.
Although the positive versus negative results represent 
the most informative RT-QuIC readout, the assay may also 
provide “quantitative” data based on the analysis of the aver-
age kinetics of seeding. To this aim, we measured the lag 
phase, the fluorescence peak, and the area under the curve 
of the fluorescence response. Differences in the average 
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values of these parameters between CSFs from patients 
with various clinical syndromes may be potentially useful 
for diagnostics and even indicative of a “strain” difference, 
as previously observed with different types of CJD in prion 
RT-QuIC reactions [6, 21, 39, 44]. Indeed, the existence of 
α-Syn strains, which may account for or contribute to the 
phenotypic heterogeneity of synucleinopathies, has been 
proposed both in vitro [10, 12, 38] and in vivo [49, 52].
Although a limited difference, though statistically sig-
nificant, in seeding activity between PD and DLB was pre-
viously noted in a relatively small patient cohort [28], we 
could not confirm this finding in our larger cohort. Indeed, 
both the lag phase and the overall fluorescence curve 
response did not vary significantly between different LB-
related clinical syndromes. Thus, at least in the current set-
ting, α-Syn RT-QuIC neither distinguished between LBD 
clinical phenotypes nor provided insight into the progression 
of symptomatic patients within the LBD clinical spectrum. 
Accordingly, α-Syn seeding activity in the CSF does not 
appear significantly correlated with the extent of LB-related 
pathology within the CNS once the LB pathology has spread 
sufficiently to cause a neurological syndrome. However, 
additional experiments, including end-point dilution sam-
ple analyses, will be needed to establish more accurately 
the relative amount of seeding activity in each patient group 
[56]. Our preliminary data obtained in a few cases with inci-
dental focal LB pathology limited to the medulla indicated 
that α-Syn seeding activity in the CSF is already detectable 
at this stage, although possibly with reduced sensitivity.
A significant strength of this study is the use of a large 
cohort pathologically verified cases to demonstrate the high 
specificity of the assay for LB-related pathology. Indeed, 
we only had two discordant results. No α-Syn deposits were 
detected by immunostaining in these cases; however, this 
analysis did not include the spinal cord, which can be an 
initial site of α-Syn accumulation. Thus, we cannot com-
pletely rule out the presence of α-Syn pathology in these two 
patients. The observed 100% specificity of the assay in the 
pre-senile control group of subjects lacking progressive neu-
rological signs seems to exclude spontaneous aggregation as 
the leading cause of false-positive results, thereby support-
ing the possibility that at least some of the few discordant 
results which we obtained may represent real evidence of 
positive α-Syn seeding activity. Indeed, given the relative 
frequency of synucleinopathies in the elderly population, 
even in the absence of neurological symptoms or signs [8, 
36, 66], the occurrence of LBs as co-pathology should also 
be considered. Thus, a few AD cases that were positive 
by RT-QuIC might also harbor LBs, at least as significant 
co-pathology.
On the opposite side, the relatively low number of neu-
ropathologically verified LBD cases, and, possibly, the lack 
of a group of fully healthy controls may be considered the 
most significant limitation of our study. However, the selec-
tion of a large clinical cohort of well-characterized patients 
with a significant clinical follow-up has likely reduced the 
discrepancy between clinical and post-mortem diagnosis at 
a minimum.
The finding that the vast majority of MSA patients, a bona 
fide synucleinopathy, did not show α-Syn seeding activity 
deserves a further comment. In the only previous study of 
this kind [64], the α-Syn RT-QuIC sensitivity for MSA was 
also quite low (35.2%, 6/17 positive cases), although not as 
low as in our experience. In another study, α-Syn protein 
misfolding cyclic amplification (PMCA) discriminated both 
PD (88.5%) and MSA (80%, 8/10 positive cases) patients 
from controls and other neurodegenerative disorders. How-
ever, the mean maximum fluorescence signal from MSA 
samples was much smaller than the corresponding signal 
from patients with PD [60]. Along this line, the same inves-
tigators recently exploited the PMCA methodology to dem-
onstrate that the different reactivity of α-Syn between PD 
and MSA can be used to discriminate between samples of 
CSF from the two groups of patients with an accuracy of 
95% [61]. The most likely explanation of our and previous 
results is that the α-Syn pathological conformer associated 
with MSA has structural constraints that limited its template 
activity in the tested RT-QuIC, the extent of which may vary 
according to the specific experimental conditions. Signifi-
cant structural differences in the α-Syn aggregates between 
MSA and PD are, indeed, increasingly recognized [59, 61, 
68]. In this scenario, our data would strongly support the 
hypothesis that MSA and LBD are linked to two distinct 
“strains” of α-Syn aggregates, while on the opposite, they 
would suggest, but not prove, that a similar α-Syn aggregate 
conformation characterizes the whole spectrum of LBD.
As an additional implication for the pathobiology of 
α-synucleinopathies, the demonstration that the CSF of 
patients belonging to the whole spectrum of LBD is capa-
ble of seeding the amyloid aggregation of wild-type α-Syn 
with high efficiency strongly supports the prion-like nature 
of these disorders.
In summary, here, we have shown the α-Syn RT-QuIC 
provides a very robust biomarker for LB-related disor-
ders, a finding that supports its rapid implementation in 
clinical practice, especially in research centers participat-
ing in patient selection for clinical trials. Given the high 
accuracy with which the assay identifies the LB-associated 
α-Syn pathology, it might also be the time to update the 
current nomenclature for iRBD, PAF, and PD, to introduce 
the eponym LB to each of these syndromes (i.e., PAF-LB, 
iRBD-LB, and PD-LB), to correctly classify patients with 
in vivo evidence for LB-related pathology obtained employ-
ing RT-QuIC or other SAAs. In this context, the application 
of RT-QuIC to genetically determined PD cases will also 
significantly contribute to establishing which are the genetic 
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defects causing an LB-related PD from those causing the 
degeneration in the substantia nigra without LB formation.
Future studies should establish the impact of α-Syn RT-
QuIC on current diagnostic criteria across the spectrum of 
LB-related disorders, determine the performance of other 
diagnostic specimens such as skin biopsies and olfactory 
brushings in comparison with CSF, evaluate the correlation 
between levels of α-Syn seeding activity and disease pro-
gression, and search for variations in the RT-QuIC set-up 
that might specifically detect α-Syn seeding activity in MSA.
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